Waldencast's Impressive Q3 2024 Financial Performance
Waldencast plc (NASDAQ: WALD), a notable name in the global beauty and wellness industry, has reported remarkable operating results for Q3 2024. Notably, the company achieved $70.2 million in net revenue, marking a healthy 34.6% increase in comparable net revenue compared to the same quarter in the previous year. This impressive revenue growth was bolstered by significant contributions from both the Obagi Medical and Milk Makeup brands, which witnessed growth rates of 45.5% and 23.5%, respectively.
Highlights of Q3 2024 Results
Michel Brousset, the founder and CEO of Waldencast, expressed satisfaction with the company's performance, stating, "We are pleased to report another quarter of strong results, with comparable net revenue growth of 34.6% and continued gross margin and adjusted EBITDA expansion." The growth reflects strong consumer demand and effective operational strategies focused on enhancing brand equity.
Revenue Growth Strength
The record net revenue of $70.2 million signifies a substantial increase over previous performance indicators. The strategic emphasis on increasing brand awareness and expanding digital distribution channels has played a crucial role in achieving this milestone.
Financial Metrics Improvement
The gross profit for Waldencast in this quarter soared to $48.1 million, a substantial increase from $35.9 million reported in Q3 2023. The adjusted gross profit reached an impressive $51.4 million, translating to a robust gross margin of 73.2%, driven by a favorable product mix and effective inventory management.
Adjusted EBITDA and Company Outlook
Waldencast’s adjusted EBITDA rose to $11.4 million, reflecting an impressive increase of 134% compared to Q3 2023. The adjusted EBITDA margin was recorded at 16.3%, showcasing operational efficiencies that offset increased marketing investments and enhanced performance across their platforms.
Liquidity and Future Direction
The company maintained a healthy liquidity position, with $17.6 million in cash and equivalents at the end of the quarter and $30 million available from its revolving credit facility. Looking ahead, Waldencast projects continued growth, anticipating comparable net revenue growth exceeding 25.7% for the full fiscal year.
Segment Performance: Obagi Medical and Milk Makeup
In terms of segment performance, Obagi Medical reported strong sales with net revenue hitting $38.7 million, supported by innovative product launches and strategic marketing initiatives. The brand experienced a notable recovery in the U.S. physician dispensed channel, indicating improving stock levels and customer demand.
Milk Makeup Insights
Meanwhile, Milk Makeup also witnessed significant growth, achieving $31.5 million in net revenue, primarily driven by robust brand momentum and expanding distribution channels across Europe. The brand’s unique offerings and engagement strategies have fostered a loyal customer base, contributing to its remarkable growth trajectory.
Conference Call and Further Developments
Waldencast plans to hold a conference call to discuss the Q3 2024 results, during which it will offer more insights and answer any questions from investors and stakeholders. This call represents an opportunity for further engagement and discussion on the company's strategies, performance, and future plans.
Frequently Asked Questions
What were Waldencast's net revenues for Q3 2024?
Waldencast reported net revenues of $70.2 million for Q3 2024.
What brands contributed to Waldencast's growth?
The growth was primarily driven by Obagi Medical with a 45.5% increase and Milk Makeup with a 23.5% increase in revenue.
How much did Waldencast's Adjusted EBITDA improve?
Waldencast’s adjusted EBITDA improved to $11.4 million, a 134% increase compared to Q3 2023.
What is Waldencast's outlook for the fiscal year?
The company expects to deliver a comparable net revenue growth exceeding 25.7% for the full fiscal year.
When will Waldencast hold its conference call?
The conference call is scheduled for November 21, 2024, at 8:30 AM ET.
